Article
Quantitative methods for developing Fc mutants with extended half-lives.
Biotechnology and bioengineering - 20 Dec 2005
Kamei Daniel T, Lao Bert J, Ricci Margaret Speed, Deshpande Rohini, Xu Han, Tidor Bruce, Lauffenburger Douglas A
Abstract excerpt
Fc mutants with increased binding affinity for the neonatal receptor, FcRn, exhibit increased half-lives in vivo, and represent an attractive means for extending the half-lives of therapeutic antibodies. The half-lives of other therapeutic molecules (e.g., proteins) may also be extended by conjugating them to Fc fragments, thus decreasing the frequency of patient injections and allowing the administration of low...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.